The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
Dai Ogata(Unknown), Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center), Adi Diab(Cleveland Clinic), Sapna P. Patel(JSS Dental College and Hospital), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Sühendan Ekmekçioglu(The University of Texas MD Anderson Cancer Center), Jennifer L. McQuade(The University of Texas MD Anderson Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Isabella C. Glitza(The University of Texas MD Anderson Cancer Center), Michael K. Wong(Roswell Park Comprehensive Cancer Center)
Cited by 31
Related Papers
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
|Science|2021|876
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822